ReNerve (ASX:RNV)
Company Profile
RELATED STOCKHEAD STORIES
StockTake: ReNerve banks $3.2M to ramp US sales and nerve-repair product rollout
Scott Power: ASX healthcare sector holds through sharp Wall Street sell-off
Closing Bell: ASX crashes out on strong jobs data as resources push higher
Health Check: EBR’s US sales are off to a heart-pumping start as clinicians take the Wise approach
Who’s Who with ReNerve: Building the future of bioengineered nerve healing
Lunch Wrap: ASX stumbles as Webjet unravels and Droneshield enters free fall
Top 10 at 11: Oil plummets but gold builds momentum as ASX struggles to find balance
ReNerve wins approval for NervAlign across US Department of Defense and VA healthcare
Biocurious: ‘My finest hour and my biggest regret’ – biotech veterans reflect on two decades in the game
Health Check: Our flu recovery prognosis is positive, CSL tells investors
ReNerve builds momentum with expanded NervAlign nerve repair study
Rise and Shine: Everything you need to know before the ASX opens
ASX Quarterly Health Wrap: Lumos lands US$317m deal as ReNerve and Vitrafy hit key milestones
